Mental disorders represent a worldwide public health concern. Psychotherapies and
pharmacotherapies are recommended as first line treatments. However, evidence has …

Rationale Major depressive disorder is one of the leading global causes of disability, for
which the classic serotonergic psychedelics have recently reemerged as a potential …

Psilocybin has shown promise for the treatment of mood disorders, which are often
accompanied by cognitive dysfunction including cognitive rigidity. Recent studies have …

Individuals with substance use disorders (SUDs) are at increased risk for COVID‐19
infection and for adverse outcomes of the infection. Though vaccines are highly effective …

Despite numerous studies on the neurobiology of depression, the etiological and
pathophysiological mechanisms of this disorder remain poorly understood. A large number …

Serotonergic psychedelics are emerging as potential antidepressant therapeutic tools, as
suggested in a recent randomized controlled trial with ayahuasca for treatment-resistant …

Public Health England exists to protect and improve the nation's health and wellbeing, and
reduce health inequalities. We do this through world-leading science, research, knowledge …

Psychedelic therapy shows promise as a novel intervention for a wide range of mental
health concerns but its therapeutic action is incompletely understood. In line with …

Background: Ayahuasca is a traditional Amazon brew and its potential antidepressant
properties have recently been explored in scientific settings. We conducted a double-blind …

BackgroundTo investigate the association between pre-trial expectancy, suggestibility, and
response to treatment in a trial of escitalopram and investigational drug, COMP360 …